Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Jul;36(4):260–266. doi: 10.1007/BF01740908

Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3

So Ohta 1,✉, Ayumi Honda 1, Yuko Tokutake 1, Hajime Yoshida 1, Nobuo Hanai 1
PMCID: PMC11038899  PMID: 8439988

Abstract

Ganglioside GD3, which is one of the major gangliosides expressed on the cell surface human tumors of neuroectodermal origin, has been studied as a target molecule for passive immunotherapy. We established ten kinds of anti-GD3 monoclonal antibodies (mAb) of the mouse IgG3 subclass by immunization with purified GD3 and melanoma cells. One of the established mAb, KM641, showed major reactivity with GD3 and minor reactivity with GQ1b out of 11 common gangliosides in an enzymelinked immunosorbent assay. Immunostaining of gangliosides, separated on thin-layer chromatography plates, using KM641 revealed that most of the melanoma cell lines contained immunoreactive GD3 and GD3-lactone at a high level, but only the adrenal gland and the urinary bladder out of 21 human normal tissues had immunoreactive GD3. In immunofluorescence, KM641 bound to a variety of living tumor cell lines especially melanoma cells, including some cell lines to which another anti-GD3 mAb R24, established previously, failed to bind. High-affinity binding of KM641 to a tumor cell line was quantified by Scatchard analysis (K d = 1.9×10−8 M). KM641 exerted tumor-killing activity in the presence of effector cells or complement against melanoma cells expressing GD3 at a high level. Not only natural killer cells but also polymorphonuclear cells were effective as the effector cells in antibody-dependent cellular cytotoxicity. Intravenous injection of KM641 markedly suppressed the tumor growth of a slightly positive cell line, C24.22 (7.2×105 binding sites/cell), as well as a very GD3-positive cell line, G361 (1.9×107 binding sites/cell), inoculated intradermally in nude mice. KM641, characterized by a high binding affinity for GD3, has the potential to be a useful agent for passive immunotherapy of human cancer.

Key words: Ganglioside, Melanoma, Monoclonal antibodies

References

  • 1.Baker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effects of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991;51:144–144. [PubMed] [Google Scholar]
  • 2.Bernhard H, Bauerschmitz J, Büschenfelde K-H, Dippold W. Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues. Int J Cancer. 1992;51:568–568. doi: 10.1002/ijc.2910510411. [DOI] [PubMed] [Google Scholar]
  • 3.Chapman PB, Yuasa H, Houghton A. Homophilic binding of mouse monoclonal antibodies. J Immunol. 1990;145:891–891. [PubMed] [Google Scholar]
  • 4.Chapman PB, Lonberg M, Houghton AN. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship between avidity, effector functions, tumor targeting, and anti-tumor activity. Cancer Res. 1990;50:1503–1503. [PubMed] [Google Scholar]
  • 5.Cheresh DA, Harper JR, Schulz G, Reisfeld RA. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA. 1984;81:5767–5767. doi: 10.1073/pnas.81.18.5767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Cheung NV, Lazarus H, Miraldi FD. Ganglioside GD2 specific monoclonal antibody 3F8: a phase-I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430–1430. doi: 10.1200/JCO.1987.5.9.1430. [DOI] [PubMed] [Google Scholar]
  • 7.Dippold W, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ. Cell-surface antigens of human malignant melanoma-definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA. 1980;77:6114–6114. doi: 10.1073/pnas.77.10.6114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Garin-Chesa P, Bevesford HR, Carrato-Mena A, Oettgen HF, Old LJ, Melamed MR, Rettig WJ. Cell surface molecules of human melanoma: immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigen systems. Am J Pathol. 1989;134:295–303. [PMC free article] [PubMed] [Google Scholar]
  • 9.Hakomori S. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res. 1985;45:2405–2405. [PubMed] [Google Scholar]
  • 10.Hanai N, Shitara K, Yoshida H. Generation of monoclonal antibodies against human lung squamous cell carcinoma and adenocarcinoma using mice rendered tolerant to normal human lung. Cancer Res. 1986;46:4438–4438. [PubMed] [Google Scholar]
  • 11.Hanai N, Nores GA, MacLeod C, Torres-Mendez C-R, Hakomori S. Ganglioside-mediated modulation of cell growth. J Biol Chem. 1988;263:10915–10915. [PubMed] [Google Scholar]
  • 12.Hanai N, Furuya A, Shitara K, Oda S, Yoshida H. Comparative studies on monoclonal antibodies raised against human gastric cancer for application to serum diagnosis of cancer. Anticancer Res. 1988;8:329–329. [PubMed] [Google Scholar]
  • 13.Hanai N, Shitara K, Furuya A, Yoshida H, Dohi T, Nudelman E, Hakomori S, Satoh S. Detailed characterization of reactivities of anti-gastric cancer monoclonal antibodies to carbohydrate antigen. Anticancer Res. 1990;10:1579–1579. [PubMed] [Google Scholar]
  • 14.He X, Wikstrand CJ, Fredman P, Månsson J-E, Svennerholm L, Bigner DD. GD3 expression by cultured human tumor cells of neuroectodermal origin. Acta Neuropathol. 1989;79:317–317. doi: 10.1007/BF00294668. [DOI] [PubMed] [Google Scholar]
  • 15.Hellström I, Brankovan V, Hellström KE. Strong anti-tumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA. 1985;82:1499–1499. doi: 10.1073/pnas.82.5.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Holm M, Mansson J-E, Vanier M-T, Svennerholm L. Gangliosides of human, bovine and rabbit retina. Biochim Biophys Acta. 1972;280:356–356. doi: 10.1016/0005-2760(72)90104-x. [DOI] [PubMed] [Google Scholar]
  • 17.Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadham S, Carswell E, Melamed MR, Oettgen H, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase-I trial in patients with malignant melanoma. Proc Natl Acad Sci USA. 1985;82:1242–1242. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside. Proc Natl Acad Sci USA. 1986;83:8694–8694. doi: 10.1073/pnas.83.22.8694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Irie RF, Matsuki T, Morton DL. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet. 1989;4:786–786. doi: 10.1016/s0140-6736(89)92606-8. [DOI] [PubMed] [Google Scholar]
  • 20.Jennemann R, Rodden A, Bauer BL, Mennel H-D, Wiegandt H. Glycosphinogolipids of human gliomas. Cancer Res. 1990;50:7444–7444. [PubMed] [Google Scholar]
  • 21.Junghans RP, Waldmann TA, Landolfi NF, Avdalovic NM, Schneider WP, Queen C. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990;50:1495–1495. [PubMed] [Google Scholar]
  • 22.Kawashima I, Tada N, Fujimori T, Tai T. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro. J Biochem (Tokyo) 1990;108:109–109. doi: 10.1093/oxfordjournals.jbchem.a123148. [DOI] [PubMed] [Google Scholar]
  • 23.Llipoulos D, Ernst C, Steplewski Z, Jambarosic JA, Rodeck U, Herlyn M, Clark WH, Koprowski H, Herlyn D. Inhibition of metastasis of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. JNCI. 1989;81:440–440. doi: 10.1093/jnci/81.6.440. [DOI] [PubMed] [Google Scholar]
  • 24.Mujoo K, Reisfeld RA, Cheung L, Rosenblum MG. A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2. Cancer Immunol Immunother. 1991;34:198–198. doi: 10.1007/BF01742313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Nudelman E, Hakomori S, Kannagi R, Levery S, Yeh M-Y, Hellström KE, Hellström I. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. J Biol Chem. 1982;257:12752–12752. [PubMed] [Google Scholar]
  • 26.Portoukalian J, Zwingelstein G, Dore J. Lipid composition of human malignant melanoma tumors of various levels of malignant growth. Eur J Biochem. 1979;94:19–19. doi: 10.1111/j.1432-1033.1979.tb12866.x. [DOI] [PubMed] [Google Scholar]
  • 27.Pukel CS, Lloyd KO, Travassor R, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. J Exp Med. 1982;115:1133–1133. doi: 10.1084/jem.155.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ravindranath MH, Tsuchida T, Morton DL, Irie RI. Ganglioside GM3: GD3 ratio as an index for the management of melanoma. Cancer. 1991;67:3029–3029. doi: 10.1002/1097-0142(19910615)67:12<3029::aid-cncr2820671217>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  • 29.Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of expression in cultured cells and tissues. Cancer Res. 1985;45:4401–4401. [PubMed] [Google Scholar]
  • 30.Shitara K, Hanai N, Kusano A, Furuya A, Yoshida H, Wada K, Watanabe T, Sato S. Application of anti-sialyl Lea monoclonal antibody, KM231, for immunotherapy of cancer. Anticancer Res. 1991;11:2003–2003. [PubMed] [Google Scholar]
  • 31.Svennerholm L. Chromatographic separation of human brain gangliosides. J Neurochem. 1963;10:613–613. doi: 10.1111/j.1471-4159.1963.tb08933.x. [DOI] [PubMed] [Google Scholar]
  • 32.Tai T, Kawashima I, Furukawa K, Lloyd KO. Monoclonal antibody R24 distinguishes between differentN-acetyl-andN-glycolyl neurominic acid derivatives of ganglioside GD3. Arch Biochem Biophys. 1988;260:51–51. doi: 10.1016/0003-9861(88)90423-7. [DOI] [PubMed] [Google Scholar]
  • 33.Tsuchida T, Ravindranath MH, Saxton RE, Irie RF. Gangliosides of human melanoma: altered expression in vivo and in vitro. Cancer Res. 1987;47:1278–1278. [PubMed] [Google Scholar]
  • 34.Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. JNCI. 1987;78:45–45. doi: 10.1093/jnci/78.1.45. [DOI] [PubMed] [Google Scholar]
  • 35.Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN. Phase-I trial of a mouse monoclonal against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol. 1988;6:1636–1636. doi: 10.1200/JCO.1988.6.10.1636. [DOI] [PubMed] [Google Scholar]
  • 36.Watarai S, Onuma M, Yasuda T. Production of monoclonal antibodies specific for gangliosides GD3. J Biochem (Tokyo) 1991;110:889–889. doi: 10.1093/oxfordjournals.jbchem.a123685. [DOI] [PubMed] [Google Scholar]
  • 37.Werkmeister JA, Triglia T, Mackay IR, Dowling JP, Varigos GA, Morstyn G, Burns GF. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3. Cancer Res. 1987;47:225–225. [PubMed] [Google Scholar]
  • 38.Winter G, Milstein C. Man-made antibodies. Nature. 1991;349:293–293. doi: 10.1038/349293a0. [DOI] [PubMed] [Google Scholar]
  • 39.Yates AJ, Thompson PK, Boesel CP, Albrightson C, Hart RW. Lipid composition of human neural tumors. J Lipid Res. 1979;20:428–428. [PubMed] [Google Scholar]
  • 40.Yeh MY, Hellström I, Abe K, Hakomori S, Hellström KE. Cell-surface antigen which is present in the ganglioside fraction and shared by human melanomas. Int J Cancer. 1982;29:269–269. doi: 10.1002/ijc.2910290308. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES